![](https://ovx8cb.p3cdn1.secureserver.net/wp-content/uploads/2020/06/Picture-for-Dendritic-Cell-Vaccine_6.9.2020-1-uai-720x708.jpg)
The Ad-p53 Dendritic Cell Therapeutic Vaccine (Ad-p53-DCV) is an investigational immune stimulating therapy designed to activate the immune system to attack tumor cells that express high levels of p53 which occurs in many types of cancer.
The Ad-p53-DCV vaccine is comprised of the cancer patient’s dendritic cells, a type of immune cell, infected in the laboratory with a genetically engineered adenovirus carrying the human p53 gene (Ad-p53).
The Ad-p53-DCV vaccine is then injected into the patient’s skin. The Ad-p53-DCV vaccination treatment is combined with Bristol Myers Squibb nivolumab and ipilimumab immune therapies. Nivolumab and ipilimumab have been approved for the treatment of other forms of cancer.